June 25, 2025 10:14 AM EDT
People
Cell/Gene Tx

Bay­er's stem cell group Blue­Rock re­struc­tures pipeline, lays off staffers

Max Gelman

Senior Editor

Bay­er sub­sidiary Blue­Rock Ther­a­peu­tics is cut­ting back on some of its cell ther­a­py work and lay­ing off sev­er­al dozen staffers.

The com­pa­ny will re­struc­ture it­self …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: FDA's Makary sought re­jec­tion of KalVista’s drug in an un­usu­al move by com­mis­sion­er, sources say

Kymera inks deal with Gilead as part­ner­ship with Sanofi faces a switch-up

FDA in­ves­ti­gat­ing Sarep­ta’s Duchenne gene ther­a­py fol­low­ing pa­tient deaths

Bright­Gene seeks a part­ner for Zep­bound-beat­ing obe­si­ty shot

Bio­gen un­veils first da­ta from Spin­raza fol­low-on, plans late-stage pro­gram

sponsored

Dig­i­tal Twins in GMP Man­u­fac­tur­ing: Shap­ing the Fu­ture of CPV with Aizon

A service from the Financial Times